BCAB BioAtla Corp Earnings per share for the last twelve months

BCAB (BioAtla Inc) - company brandmark

BioAtla, Inc. (BCAB) management effectively coordinates R&D and fundraising, protecting the CAB platform. Annual net income per share illustrates the current return, where -25.44 represents the latest level. Patent protection for prodrugs creates barriers for competitors lacking significant capital, while long-term margins now depend on the results of phase II clinical trials.

BCAB (BioAtla, Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 09/06/2026

BioAtla Inc - analytical breakdowns and key metrics (BCAB)

- current quotes and average value forecast:
Price Chart BioAtla Corp|BCAB - Average Forecast Price
- market capitalization data:
Market Value BioAtla, Inc.|BCAB - Business Value
- shareholders' equity book value data:
Book Value per Share BioAtla|BCAB - Company Net Assets|Market Value to Book Value Ratio bioatla.com|BCAB - Company Assets
- debt burden and liquidity indicators:
Debt to Equity BioAtla, Inc.|BCAB - Long-Term Debt to Equity|Short-Term Debt to Equity BioAtla Corp|BCAB - Company Cumulative Debt|Debts to Book Capitalization BioAtla, Inc.|BCAB - Long-Term Indebtedness|Company Current Liabilities BioAtla|Quick Liquidity Indicator bioatla.com
- net income and valuation multiples indicators:
BCAB - Final Profit|Future Profit BioAtla, Inc.|BCAB - Market Price to Net Income Ratio|Forward P/E Multiple BioAtla Corp|BCAB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple BioAtla, Inc.|BCAB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months BioAtla|BCAB - Earnings per share for the trailing year|Quarterly EPS earnings growth bioatla.com|BCAB - Earnings growth in current year|Net earnings per share growth forecast for next year BioAtla, Inc.
Basic company analysis:bioatla.com (BCAB)
Mass-produced product of BioAtla Corp

Annual net earnings per share measures real equity returns by dividing the final financial result by the total number of securities. This metric allows an investor to assess capital management efficiency without the distortions of quarterly reporting. By analyzing the rolling 12-month EPS, one can identify the hidden impact of share buybacks on equity value. For BioAtla, Inc. (BCAB), such dynamics are critical amid risks of raw material logistics disruptions. Geopolitical barriers in patent protection directly impact the issuer's bottom line.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months hutch-med.com|Nuvation Bio (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (Monopar Pharma) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Inhibrx Corp (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics, Inc. HRTX|Nuvectis Pharma Inc. - Earnings per share for the last twelve months|CHRS - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Corbus Pharmaceuticals, Inc.|CRDF: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year beyondspringpharma.com BYSI|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharma CTXR|Net earnings per share for the last 12 months CLRB (Cellectar)|BLRX (BioLineRx Corporation) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea Therapeutics Inc.)|Kazia - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (Silexion Therapeutics Corp)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Chimerix Inc (CMRX)|Earnings per share for the last twelve months Cyclacel Pharmaceuticals|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Therapeutics Inc (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech Corp) - Earnings per one share for the last 12 months